CyFlow™ CD61 FITC
Alternative Name: | GPIIIa |
Antigen: | CD61 |
Application: | Flow cytometry |
Clonality: | monoclonal |
Clone: | VIPL2 |
Emission Maximum: | 518 nm |
Excitation Maximum: | 490 to 495 nm |
Field of Interest: | Immunophenotyping |
Format/Fluorochrome: | FITC |
Isotype: | IgG1 |
Laser: | Blue |
Regulatory Status: | CE IVD |
Source Species: | Mouse |
Target Species: | Human |
Product number: | AR902616 |
CE IVD
HLDA Workshop | HLDA V—WS Code 5T-124 |
Concentration Unit | µg/mL |
Concentration | 50 |
Quantity | 100 tests |
Volume | 1.0 mL |
Immunogen | Not available |
Background Information | CD61 (β3 integrin) is a transmembrane glycoprotein, which associates with CD41 or CD51 molecules to form heterodimeric adhesion receptores. CD41/CD61 complex is one of the earliest markers of the megakaryocytic lineage. It binds to fibronectin, fibrinogen and von Willebrand factor, and is involved in platelet aggregation. CD51/CD61 complex has similar binding properties and is involved in modulating migration and survival of angiogenic endothelial cells. |
Antigen Distribution | CD61 (GPIIIa) is a 90-110 kDa transmembrane glycoprotein (integrin family) expressed on platelets, megacaryocytes, osteoclasts, endothelial cells and other cell types, including leukocytes and smooth muscle cells. CD61 associates with CD41 or CD51 molecules to form heterodimeric adhesion receptors. CD41/CD61 complex is one of the earliest markers of the megakaryocytic lineage. It binds to fibronectin, fibrinogen and von Willebrand factor, and is involved in platelet aggregation. CD51/CD61 complex is involved in modulating migration and survival of angiogenic endothelial cells. |
Usage | CE IVD usage Placeholder |
Storage Buffer | The reagent is provided in stabilizing phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide and 0.2% (w/v) BSA. |
Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
Stability | Do not use after expiration date stamped on vial label. |
| Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J: BDCA‑2, BDCA‑3, and BDCA‑4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000 Dec 1; 165(11):6037‑46. < PMID: 11086035 > | Ciarlet M, Crawford SE, Cheng E, Blutt SE, Rice DA, Bergelson JM, Estes MK: VLA‑2 (alpha2beta{01} integrin promotes rotavirus entry into cells but is not necessary for rotavirus attachment. J Virol. 2002 Feb; 76(3):1109‑23. < PMID: 11773387 > | Roberts MS, Woods AJ, Dale TC, Van Der Sluijs P, Norman JC: Protein kinase B/Akt acts via glycogen synthase kinase 3 to regulate recycling of alpha v beta 3 and alpha 5 beta 1 integrins. Mol Cell Biol. 2004 Feb; 24(4):1505‑15. < PMID: 14749368 > | Mondal D, Williams CA, Ali M, Eilers M, Agrawal KC: The HIV‑1 Tat protein selectively enhances CXCR4 and inhibits CCR5 expression in megakaryocytic K562 cells. Exp Biol Med (Maywood). 2005 Oct; 230(9):631‑44. < PMID: 16179731 > | Williams CA, Mondal D, Agrawal KC: The HIV‑1 Tat protein enhances megakaryocytic commitment of K562 cells by facilitating CREB transcription factor coactivation by CBP. Exp Biol Med (Maywood). 2005 Dec; 230(11):872‑84. < PMID: 16339753 > | Barrett L, Dai C, Gamberg J, Gallant M, Grant M: Circulating CD14‑CD36+ peripheral blood mononuclear cells constitutively produce interleukin‑10. J Leukoc Biol. 2007 Jul; 82(1):152‑60. < PMID: 17412916 >